About Faro Molecular
At Faro Molecular, we are at the forefront of biotechnological innovation, specializing in self-contained fluid handling, real-time PCR and DNA melting analysis. Our groundbreaking platform is set to transform biomedical diagnostics by introducing a next-generation, highly multiplexed system tailored for both biomedical research and diagnostic applications.
Rapid and Robust Molecular Biology Workflow
Our goal is to automate complex molecular biology reactions (affinity capture, multiplex PCR, DNA melting curve analysis) in a format that is simultaneously self-contained, flexible, inexpensive to operate and capable of analyzing hundreds of targets in a single sample. A combination of automation and careful optimization enables rapid time to result. Fast protocols are essential for timely decision-making in clinical environments and for improving efficiency in the research environment.
Advancing Oncology and Age-Related Disease Research
Faro Molecular is dedicated to advancing the field of epigenetic marker quantification, with a keen focus on oncology and aging-related diseases. Our technology enables precise measurement of epigenetic changes, providing critical insights that drive the development of targeted therapies and improve patient outcomes.
Expert Driven
The backbone of Faro Molecular is our team, composed of seasoned experts who bring decades of experience from leading companies in PCR technology. Their deep expertise ensures that our platforms are not only innovative but also aligned with the highest industry standards.
Our Management Team
Kirk Ririe
Chief Executive Officer
Kirk Ririe
Chief Executive Officer & Chairman of the Board of Directors
Kirk Ririe brings more than 30 years of business and scientific experience in private and publicly held PCR companies. Most recently he was CEO of Idaho Molecular which was acquired by Co-Diagnostics where he served as President of the wholly owned subsidiary. He previously served as Chief Innovation Officer at bioMérieux, CEO of BioFire Defense, CEO of BioFire Diagnostics and Chairman, President and CEO of Idaho Technology. Kirk was integral in the development and a contributing inventor of the RapidCycler, LightCycler, Razor and FilmArray PCR systems. He was the recipient of the 2004 Utah Ernst & Young Entrepreneur of the Year Award.
Kirk founded, grew and successfully exited multiple companies including Idaho Technology, which was sold to bioMérieux in 2008 and Idaho Molecular which sold to Co-Diagnostics in 2021. He has served on the Board of Directors for a variety of companies in the BioTech and Technology spaces.
Kirk earned a BS in Chemistry and was awarded an Honorary Doctorate from the University of Utah.
Mark Poritz
Chief Scientist Officer
Mark Poritz
Chief Scientific Officer
Dr. Poritz has spent the last 28 years working on infectious disease therapeutics and diagnostics. He joined Idaho Technology in 2002 to write the NIH grant that funded the initial development of the FilmArray IVD platform. He led the development of the chemistry and molecular biology aspects of the first FilmArray product – the respiratory pathogen panel. After the acquisition of Idaho Technology/BioFire by bioMérieux, Dr. Poritz became Vice President of Chemistry Research at BioFire Defense. There he led the development of the US Department of Defense FilmArray Global Fever panel.
During the pandemic he was the CSO of the Co-Diagnostics subsidiary, Idaho Molecular, and subsequently CSO of the parent company. At Co-Dx he supervised the development of the biochemical reagents for the Co-Dx PCR Pro platform.
Dr. Poritz received his undergraduate degree from Harvard College and his PhD in Genetics from the University of California at San Francisco.
Rocky Taylor
Chief Financial Officer
Rocky Taylor
Chief Financial Officer & Board Member
Rocky Taylor brings more than 30 years of business experience in private and publicly held companies. Most recently he was CFO of Idaho Molecular which was acquired by Co-Diagnostics where he served as CFO of the wholly owned subsidiary. He previously served as CFO for HydrantID, a data encryption company, which was acquired in 2019 by HID. Prior to that he was integral in founding, growing or exiting multiple companies across a variety of industries including retail, rail, technology and fashion brands.
Rocky earned a BS in Marketing and an MBA from the University of Utah.
Our Board of Directors
Kirk
Ririe
Rocky
Taylor
Noriko
Kusukawa
Carl
Wittwer
Contact
Address: 3165 South 300 West, SLC, Utah 84115
Email us: info@faromolecular.com